Suresh Boppana

Dr. Suresh Boppana

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
PDF file
SMSheetal Manicklal
Sheetal Manicklal
VEVincent C. Emery
Vincent C. Emery
TLTiziana Lazzarotto
Tiziana Lazzarotto
SBSuresh Boppana
Suresh Boppana
RGRavindra Gupta
Ravindra Gupta
SUMMARY: Human cytomegalovirus (CMV) is a leading cause of congenital infections worldwide. In the developed world, following the virtual elimination of circulating rubella, it is the commonest nongenetic cause of childhood hearing loss and an important cause of neurodevelopmental delay. The seroprevalence of CMV in adults and the incidence of congenital CMV infection are highest in developing countries (1 to 5% of births) and are most likely driven by nonprimary maternal infections. However, reliable estimates of prevalence and outcome from developing countries are not available. This is largely due to the dogma that maternal preexisting seroimmunity virtually eliminates the risk for sequelae. However, recent data demonstrating similar rates of sequelae, especially hearing loss, following primary and nonprimary maternal infection have underscored the importance of congenital CMV infection in resource-poor settings. Although a significant proportion of congenital CMV infections are attributable to maternal primary infection in well-resourced settings, the absence of specific interventions for seronegative mothers and uncertainty about fetal prognosis have discouraged routine maternal antibody screening. Despite these challenges, encouraging results from prototype vaccines have been reported, and the first randomized phase III trials of prenatal interventions and prolonged postnatal antiviral therapy are under way. Successful implementation of strategies to prevent or reduce the burden of congenital CMV infection will require heightened global awareness among clinicians and the general population. In this review, we highlight the global epidemiology of congenital CMV and the implications of growing knowledge in areas of prevention, diagnosis, prognosis, and management for both low (50 to 70%)- and high (>70%)-seroprevalence settings.

3 May 2001 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SBSuresh Boppana
Suresh Boppana
LRLisa B. Rivera
Lisa B. Rivera
KFKaren B. Fowler
Karen B. Fowler
MMMichael Mach
Michael Mach
WBWilliam J. Britt
William J. Britt
Preconceptional immunity against cytomegalovirus (CMV) provides only partial protection against intrauterine transmission of the virus. Whether congenital CMV infection in the offspring of women who are seropositive for CMV can occur after maternal reinfection with a different strain of CMV is unknown.

2 June 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SBSuresh Boppana
Suresh Boppana
SRShannon A. Ross
Shannon A. Ross
MSMasako Shimamura
Masako Shimamura
APApril L. Palmer
April L. Palmer
AAAmina Ahmed
Amina Ahmed
KFKaren B. Fowler
Karen B. Fowler
Congenital cytomegalovirus (CMV) infection is an important cause of hearing loss, and most infants at risk for CMV-associated hearing loss are not identified early in life because of failure to test for the infection. The standard assay for newborn CMV screening is rapid culture performed on saliva specimens obtained at birth, but this assay cannot be automated. Two alternatives — real-time polymerase-chain-reaction (PCR)–based testing of a liquid-saliva or dried-saliva specimen obtained at birth — have been developed. In our prospective, multicenter screening study of newborns, we compared real-time PCR assays of liquid-saliva and dried-saliva specimens with rapid culture of saliva specimens obtained at birth. A total of 177 of 34,989 infants (0.5%; 95% confidence interval [CI], 0.4 to 0.6) were positive for CMV, according to at least one of the three methods. Of 17,662 newborns screened with the use of the liquid-saliva PCR assay, 17,569 were negative for CMV, and the remaining 85 infants (0.5%; 95% CI, 0.4 to 0.6) had positive results on both culture and PCR assay. The sensitivity and specificity of the liquid-saliva PCR assay were 100% (95% CI, 95.8 to 100) and 99.9% (95% CI, 99.9 to 100), respectively, and the positive and negative predictive values were 91.4% (95% CI, 83.8 to 96.2) and 100% (95% CI, 99.9 to 100), respectively. Of 17,327 newborns screened by means of the dried-saliva PCR assay, 74 were positive for CMV, whereas 76 (0.4%; 95% CI, 0.3 to 0.5) were found to be CMV-positive on rapid culture. Sensitivity and specificity of the dried-saliva PCR assay were 97.4% (95% CI, 90.8 to 99.7) and 99.9% (95% CI, 99.9 to 100), respectively. The positive and negative predictive values were 90.2% (95% CI, 81.7 to 95.7) and 99.9% (95% CI, 99.9 to 100), respectively. Real-time PCR assays of both liquid- and dried-saliva specimens showed high sensitivity and specificity for detecting CMV infection and should be considered potential screening tools for CMV in newborns. (Funded by the National Institute on Deafness and Other Communication Disorders.)

20 November 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SBSuresh Boppana
Suresh Boppana
SRShannon A. Ross
Shannon A. Ross
KFKaren B. Fowler
Karen B. Fowler
Congenital cytomegalovirus (CMV) infection is a leading cause of hearing loss and neurologic disabilities in children worldwide. Infants with symptomatic congenital CMV infection at birth are at significantly increased risk for developing adverse long-term outcomes. The vast majority of infants with congenital CMV infection have no clinical findings at birth (asymptomatic infants), and about 10%–15% of these children develop long-term sequelae. Currently, predictors of adverse outcome in asymptomatic congenital CMV infection are not known, and it is important that future studies address this issue.

14 April 2010 in JAMA
Verified
Journal Article
Open access
PDF file
SBSuresh Boppana
Suresh Boppana
SRShannon A. Ross
Shannon A. Ross
ZNZdenek Novak
Zdenek Novak
MSMasako Shimamura
Masako Shimamura
RTRobert W. Tolan
Robert W. Tolan
OCOther Communication Disorders Cmv
Other Communication Disorders Cmv
Cytomegalovirus (CMV) is an important cause of congenital infection and a leading cause of sensorineural hearing loss (SNHL) in children.1-5 Of the estimated 20 000 to 40 000 infants born each year with congenital CMV infection in the United States, most (90% to 95%) have no detectable clinical abnormalities at birth and thus will not be identified by routine clinical examination.2,6,7 Furthermore, SNHL occurs in approximately 10% to 15% of infants with clinically inapparent congenital CMV infection and the majority of children with CMV-related SNHL will have late-onset losses, progressive losses, or both.1,8,9 Therefore, both routine physical examination and newborn hearing screening will miss potential diagnosis in many children who develop SNHL secondary to congenital CMV infection. To identify these at-risk infants early in life, rapid, reliable, and relatively inexpensive methods to screen newborns for congenital CMV infection are needed.10 Identification of children at increased risk of CMV-associated SNHL early in life will allow targeted monitoring of these children in order to intervene at critical stages of acquiring speech and language skills.11

1 July 1999 in Pediatrics
Verified
Journal Article
Closed access
PDF file
SBSuresh Boppana
Suresh Boppana
KFKaren B. Fowler
Karen B. Fowler
WBWilliam J. Britt
William J. Britt
SSSergio Stagno
Sergio Stagno
RPRobert F. Pass
Robert F. Pass
Objectives.: To determine the frequency of symptomatic congenital cytomegalovirus (CMV) infection in the offspring of women with a recurrent maternal CMV infection and to characterize the demographic and newborn findings. Methods.: Study subjects consisted of infants with symptomatic congenital CMV infection identified by a newborn virologic screening program at the University of Alabama Hospital between 1991 and 1997 and were enrolled in a long-term follow-up study. Maternal infections were categorized by an analysis of archival serum specimens collected before pregnancy and at the time of delivery. Demographic data and clinical findings at birth were collected from maternal and newborn hospital records and from parents at the time of initial evaluation. Results.: Of the 47 infants with symptomatic congenital CMV infection identified during the study period, 8 were born to mothers with a confirmed nonprimary or recurrent CMV infection. The type of maternal infection could be ascertained in only ∼43% (20/47) of the children with symptomatic congenital CMV infection born at the University of Alabama Hospital during the study period. There were no significant differences in demographic characteristics of the recurrent infection group and the infants who were born to mothers with either primary CMV infection during pregnancy or unclassified maternal infection. Similarly, the range of severity of clinical abnormalities during the newborn period did not differ in the two groups of children. Furthermore, there were no significant differences in the incidence of sequelae at long-term follow-up in the two groups of children. Conclusions.: Symptomatic congenital CMV infection can occur after a nonprimary or recurrent maternal infection. However, the exact incidence of symptomatic congenital CMV infection among children born to women with preexisting immunity remains to be defined.